What is HC Wainwright’s Estimate for Immunocore Q3 Earnings?

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Research analysts at HC Wainwright raised their Q3 2027 earnings per share (EPS) estimates for shares of Immunocore in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.39 per share for the quarter, up from their previous forecast of $0.28. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for Immunocore’s Q4 2027 earnings at $0.49 EPS and FY2028 earnings at $4.53 EPS.

Immunocore (NASDAQ:IMCR) last released its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The business had revenue of $115.93 million during the quarter, compared to analyst estimates of $148.57 million. Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%.

Other equities research analysts also recently issued research reports about the stock. Mizuho raised their price objective on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Finally, Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $57.29.

Immunocore Stock Up 1.6%

Shares of IMCR stock opened at $34.74 on Thursday. Immunocore has a 12 month low of $27.56 and a 12 month high of $40.71. The firm has a market cap of $1.77 billion, a PE ratio of -93.89 and a beta of 0.74. The stock has a 50 day moving average of $31.95 and a 200-day moving average of $31.33. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94.

Hedge Funds Weigh In On Immunocore

Hedge funds have recently made changes to their positions in the business. Hussman Strategic Advisors Inc. bought a new stake in shares of Immunocore in the 4th quarter valued at approximately $1,458,000. Eversept Partners LP bought a new position in shares of Immunocore during the 1st quarter worth approximately $1,183,000. Eschler Asset Management LLP boosted its stake in Immunocore by 100.0% in the 4th quarter. Eschler Asset Management LLP now owns 80,000 shares of the company’s stock valued at $2,777,000 after buying an additional 40,000 shares in the last quarter. Janus Henderson Group PLC grew its position in Immunocore by 30.9% in the first quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock valued at $17,919,000 after acquiring an additional 140,308 shares during the period. Finally, Stempoint Capital LP bought a new stake in Immunocore in the first quarter valued at $1,916,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.